Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer Aviation Inc (ACHR) vs Cassava Sciences Inc (FLNA) Price & Performance

Archer Aviation IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs Cassava Sciences Inc — how do they compare? Archer Aviation Inc trades at $6.37 (market cap $5.23B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Archer Aviation Inc is far larger — about 109.5× Cassava Sciences Inc's market cap, and Archer Aviation Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ACHRFLNA
Market Cap
$5.23B$47.75M
Sector
IndustrialsHealth
52-Week High
$13.64$4.64
52-Week Low
$4.44$0.87
Enterprise Value
$3.79B-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer Aviation Inc

Archer Aviation (ACHR) trades at $6.41, up 2.4% today, with a bullish technical signal from moving averages. The stock shows strong analyst support (78% buy ratings) amid recent news of a strategic Boeing deal to acquire three businesses, boosting its defense and AI aviation portfolio. However, fundamentals remain weak with a P/S ratio of 719.85 and deeply negative profit margins, as the company is pre-revenue and burning cash to develop its eVTOL technology.

Outlook hinges on successful commercialization of air taxis and integration of Boeing assets, offering growth potential but carrying high execution risk. Investors face substantial losses until revenue scales, with net income margin at -11,590% in 2026. The Boeing partnership provides a cash flow bridge via defense revenue, yet dilution from equity offerings and regulatory delays pose near-term headwinds.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

Read more on ACHR

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA